Entity

Gate2Brain

Biotechnology - Therapeutics and Diagnostics

Associated Company

 

Gate2Brain SL is an early-stage biotech company launched to improve drug delivery across biological barriers through the use of a radically innovative peptide-based patented technology. Our lead asset (G2B-001) is a first-in-class therapeutic approach for solid tumors presenting harsh barriers to anticancer drug delivery. We focus on pediatric diseases such as Diffuse Intrinsic Pontine Glioma (DIPG).

+34 677 522 679

info@gate2brain.com

gate2brain.com


Contact person: Meritxell Teixidó Turà